Newsletter | September 16, 2024

09.16.24 -- The Future Of MDMA-Assisted Therapy After FDA Rejection — Where Do We Go Now?

CLINICAL SITES

How Study Sponsors Are Taming The Competitive Enrollment Stampede

Free-for-all competitive enrollment may achieve quick enrollment but might harm site efficiency and satisfaction. Site Council Executive Director Norman M. Goldfarb offers managed competitive enrollment as an alternative.

Trends In Sponsor-Of-Choice Initiatives: Consolidating Site Payments

Listen in as leaders from Bristol Myers Squibb, CenExel Centers of Excellence, and IQVIA Technologies discuss the importance of providing a consistent clinical trial payment experience to sites.

The Asia Advantage: Why US Biotechs Should Look East

Explore the compelling reasons behind the Asia Advantage and highlights how Avance Clinical's strategic expansion into the region supports biotechs in maximizing these benefits.

Get Your Tile Into One Home for Sites™

When you "get your tile" into One Home, you're building up the library of systems available to sites for single sign-on and task management across their trials.

Take Full Control Of Site Payments With iMednet Payments

See how iMednet Payments can streamline site budget management, payment approvals, and transaction tracking with fast, error-free automation for study administrators.

Why Sites Around The World Love Clincard

We surveyed sites around the world! Hear what they have to say about how ClinCard's global capabilities have helped better their trials.

PATIENT CENTRICITY

The Future Of MDMA-Assisted Therapy After FDA Rejection — Where Do We Go Now?

After the recent FDA rejection of MDMA-assisted therapy for PTSD, psychedelic drug developers and mental health experts alike are asking (and answering), "Where do we go now?"

Database To Advance Patient-Focused Drug Development With DHTs

Uncover how the Patient-Focused Digital Measure Report Database leverages patient-reported data to highlight specific indications where DHTs can provide meaningful, patient-centric measures.

PATIENT RECRUITMENT

A Vision For Inclusion: Designing Trials That Benefit Visually Impaired Patients

Ocugen CMO Huma Qamar, MD, MPH, CMI contends that whether targeting vision-related conditions or other medical needs, sponsors must design trials that ensure vision-impaired patients are included.

PATIENT RECRUITMENT - INDUSTRY INSIGHTS

Rare Disease Research: Finding Participants And Driving Progress

Discover where to find participants for rare disease studies, how to leverage ongoing funding and advocacy for rare disease cures, and strategies to enhance recruitment and engagement in your trials.

4 Ways To Increase Diversity In Clinical Trials

Here, we provide diversity strategies that encompass every facet of the trial lifecycle, such as the design of a patient-centric experience, positioning for regulatory and operational success, and more.

CHOOSE YOUR OWN ADVENTURE

You're receiving the Monday edition of the Clinical Leader newsletter, focusing on Clinical SitesPatient Centricity, and Patient Recruitment. To make changes to your newsletter selections, update your topic preferences.

  • Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
  • Clinical Trial Technology (Tuesday)
  • Decentralized Trials | Trial Management (Wednesday)
  • Outsourcing Models | Regulatory & Compliance (Thursday)
  • Clinical Data Management & Analytics | Trial Monitoring (Friday)

Learn more about our personalized newsletters here.

Connect With Clinical Leader: